Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Advances in Pharmacology (San Diego, Calif.)
|
July 4, 2020
Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants
Jaskaran B Singh, Maggie Fedgchin, Ella J Daly, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 23, 2025
Alzheimer's Imaging Consortium
Ziad S Saad, Ritobrato Datta, Maggie Fedgchin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 24, 2025
Biomarkers
Ziad S Saad, Ritobrato Datta, Maggie Fedgchin, et al.
Journal of Clinical Pharmacology
|
October 13, 2025
A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of Posdinemab (JNJ-63733657) in Healthy Chinese Adults
Fangfang Wang, Juanfang Liu, Daisy Bai, et al.
The Lancet. Psychiatry
|
February 24, 2020
Approval of esketamine for treatment-resistant depression
Jaskaran B Singh, Ella J Daly, Maju Mathews, et al.
Journal of Affective Disorders
|
December 2, 2020
Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant
Stacie Hudgens, Lysbeth Floden, Michael Blackowicz, et al.
The International Journal of Neuropsychopharmacology
|
May 6, 2020
Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials
Ziad Saad, Derrek Hibar, Maggie Fedgchin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Drug Development
Martine Meyer, David Henley, Jennifer Bogert, et al.
The American Journal of Psychiatry
|
April 17, 2018
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study
Carla M Canuso, Jaskaran B Singh, Maggie Fedgchin, et al.
Focus (American Psychiatric Publishing)
|
February 5, 2020
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study
Carla M Canuso, Jaskaran B Singh, Maggie Fedgchin, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Advances in Pharmacology (San Diego, Calif.)
|
July 4, 2020
Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants
Jaskaran B Singh, Maggie Fedgchin, Ella J Daly, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 23, 2025
Alzheimer's Imaging Consortium
Ziad S Saad, Ritobrato Datta, Maggie Fedgchin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 24, 2025
Biomarkers
Ziad S Saad, Ritobrato Datta, Maggie Fedgchin, et al.
Journal of Clinical Pharmacology
|
October 13, 2025
A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of Posdinemab (JNJ-63733657) in Healthy Chinese Adults
Fangfang Wang, Juanfang Liu, Daisy Bai, et al.
The Lancet. Psychiatry
|
February 24, 2020
Approval of esketamine for treatment-resistant depression
Jaskaran B Singh, Ella J Daly, Maju Mathews, et al.
Journal of Affective Disorders
|
December 2, 2020
Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant
Stacie Hudgens, Lysbeth Floden, Michael Blackowicz, et al.
The International Journal of Neuropsychopharmacology
|
May 6, 2020
Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials
Ziad Saad, Derrek Hibar, Maggie Fedgchin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Drug Development
Martine Meyer, David Henley, Jennifer Bogert, et al.
The American Journal of Psychiatry
|
April 17, 2018
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study
Carla M Canuso, Jaskaran B Singh, Maggie Fedgchin, et al.
Focus (American Psychiatric Publishing)
|
February 5, 2020
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study
Carla M Canuso, Jaskaran B Singh, Maggie Fedgchin, et al.
Page
of 2